ULTRAGENYX PHARMACEUTICAL INC. Contract Liability (Deferred Revenue)
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Contract Liability (Deferred Revenue) of $4.44 million as of 2022-06-30, per its 10-Q filed 2022-07-29.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2022-07-29
- 2022-06-30: Contract with Customer, Liability, Current $4.44M.
- 2022-03-31: Contract with Customer, Liability, Current $5.87M.
- 2021-12-31: Contract with Customer, Liability, Current $9.08M.
- 2021-06-30: Contract with Customer, Liability, Current $3.91M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-06-30 | $4.44M 10-Q · filed 2022-07-29 |
| 2022-03-31 | $5.87M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $9.08M 10-Q · filed 2022-07-29 |
| 2021-06-30 | $3.91M 10-Q · filed 2022-07-29 |
| 2021-03-31 | $25.09M 10-Q · filed 2022-05-06 |
| 2020-12-31 | $66.57M 10-Q · filed 2022-07-29 |
| 2020-09-30 | $102.90M 10-Q · filed 2020-10-27 |
| 2020-06-30 | $134.90M 10-Q · filed 2021-08-03 |
| 2020-03-31 | $145.28M 10-Q · filed 2021-05-05 |
| 2020-03-30 | $145.28M 10-Q · filed 2020-05-07 |
| 2019-09-30 | $16.00K 10-Q · filed 2020-10-27 |
| 2019-06-30 | $55.00K 10-Q · filed 2020-07-30 |
| 2019-03-31 | $69.00K 10-Q · filed 2019-05-07 |
| 2019-03-30 | $69.00K 10-Q · filed 2020-05-07 |
| 2018-06-30 | $1.24M 10-Q · filed 2019-08-02 |
| 2017-12-31 | $5.99M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |